Experimental Epilepsy Group

Organisational unit: Research group

Research areas and keywords

UKÄ subject classification

  • Neurology

Research

Epilepsy is one of the most devastating neurological diseases, affecting at least 60 million people worldwide. But despite certain progress in antiepileptic drug developmental, available pharmacological treatments are only symptomatic, have side effects and fail to adequately control seizures in a third of patients. Recently, neuropeptides and neurotrophic factors emerged as strong regulators of synaptic transmission in the CNS, offering a potent tool to counteract the seizure activity. However, it is not clear yet what the role of these agents is in mechanisms of epileptogenesis. We do research to develop gene therapy strategies based on neuropeptides and neurotrophic factors. We also use optogenetics and chemogenetics as tools to investigate mechanisms of epileptogenesis with the aim to develop these techniques as possible therapeutic approach to suppress seizures.

Recent research outputs

Tönnesen, J. & Merab Kokaia 2017 Jul 15 In : Clinical Science. 131, 14, p. 1605-1616 12 p.

Research output: Contribution to journalReview article

Avaliani, N., M. Andersson, Runegaard, A. H., Woldbye, D. & M. Kokaia 2016 Oct 1 In : Gene Therapy. 23, 10, p. 760-766 7 p.

Research output: Contribution to journalArticle

Pitkänen, A., Löscher, W., Vezzani, A., Becker, A. J., Simonato, M., Lukasiuk, K., Gröhn, O., Bankstahl, J. P., Friedman, A., Aronica, E., Gorter, J. A., Ravizza, T., Sisodiya, S. M., Merab Kokaia & Beck, H. 2016 Jul 1 In : Lancet Neurology. 15, 8, p. 843-856 14 p.

Research output: Contribution to journalReview article

View All (27)